URGN
UroGen Pharma Ltd.
NASDAQ · Healthcare · Biotechnology · US
$34.15
−1.19%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$34.80
From 52W high−32.09%
Volume1.26M
Market cap$1.67B
P/E (TTM)—
P/S (TTM)8.8x
Div yield—
Key dataOct 19, 2026
Open
$34.80
From 52W high
−32.09%
Volume
1.26M
Market cap
$1.67B
ValuationView details →
P/E (Fwd)
20.3x
EV/EBITDA
−25.1x
P/E (TTM)
—
RSI (14)
26.2
MomentumView details →
1D Return
−1.19%
YTD Return
+44.15%
SummaryUpdated Jun 1, 2026
UroGen Pharma Ltd. (NASDAQ:URGN) is a biotechnology company founded in 2004 and based in Princeton, New Jersey, that specializes in developing and commercializing novel treatments for specialty cancers and urothelial diseases. The company went public in May 2017 and has established itself as a focused player in the urological oncology space, with its flagship product <b>JELMYTO</b> already commercialized and a promising pipeline of investigational therapies targeting various forms of bladder and upper tract cancers.
Similar companies
Latest newsMore news →
The U.S. Food and Drug Administration accepted UroGen Pharma Ltd.’s NDA for investigational UGN-103 to treat adults with recurrent LG-IR-NMIBC and set a PDUFA target action date of June 14, 2027.12h agoUroGen Pharma entered into a strategic collaboration and investment agreement with IntraGel to access its biodegradable sustained-release gel platform and expand its oncology pipeline.61d ago